O'Donnell Anne E
Division of Pulmonary, Critical Care and Sleep Medicine, Georgetown University Medical Center, Washington, DC, USA.
Curr Opin Pulm Med. 2015 May;21(3):272-7. doi: 10.1097/MCP.0000000000000152.
In 2010, the British Thoracic Society published a guideline for the care of patients with noncystic fibrosis (non-CF) bronchiectasis; other recent clinical review articles and original scientific manuscripts have also studied the use of antibiotics in bronchiectasis. This review will summarize the current literature on the indications and options for antibiotic treatment in bronchiectasis.
Since 2012, a number of manuscripts have been published that provide evidence to support the use of antibiotics in non-CF bronchiectasis, including macrolide antibiotics, inhaled aminoglycosides and inhaled fluoroquinolone therapies. However, data remain preliminary and there are phase 3 trials underway to further investigate the efficacy and safety of antibiotics in non-CF bronchiectasis.
Although there are currently no U.S. Food and Drug Administration (FDA)-approved antibiotics for the treatment of patients with bronchiectasis, this review will highlight the current state of the science with regard to antibiotics that may be effective in non-CF bronchiectasis as well as highlighting those in development to treat this complex disease.
2010年，英国胸科学会发布了非囊性纤维化（非CF）支气管扩张症患者的护理指南；近期其他临床综述文章和原始科学手稿也对支气管扩张症中抗生素的使用进行了研究。本综述将总结目前关于支气管扩张症抗生素治疗适应证和选择的文献。
自2012年以来，已发表了多篇手稿，为非CF支气管扩张症中使用抗生素提供了证据支持，包括大环内酯类抗生素、吸入性氨基糖苷类和吸入性氟喹诺酮类疗法。然而，数据仍属初步，目前正在进行3期试验以进一步研究抗生素在非CF支气管扩张症中的疗效和安全性。
尽管目前尚无美国食品药品监督管理局（FDA）批准用于治疗支气管扩张症患者的抗生素，但本综述将突出关于可能对非CF支气管扩张症有效的抗生素的当前科学状况，并着重介绍正在研发用于治疗这种复杂疾病的抗生素。
